{"id":"trivalent-opv-sanofi-pasteur","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fever"},{"rate":"null","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL3923877","moleculeType":"Small molecule","molecularWeight":"406.48"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by introducing a weakened form of the poliovirus to the body, which triggers an immune response and helps the body develop antibodies to fight the virus. This provides immunity against poliovirus types 1, 2, and 3.","oneSentence":"Trivalent OPV Sanofi Pasteur is a vaccine that stimulates the body's immune response to protect against poliovirus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:11.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis"}]},"trialDetails":[{"nctId":"NCT03614702","phase":"PHASE3","title":"Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2015-09-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420},{"nctId":"NCT01870206","phase":"PHASE3","title":"Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns","status":"UNKNOWN","sponsor":"Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.","startDate":"2013-06","conditions":"Poliomyelitis","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["tOPV"],"phase":"phase_3","status":"active","brandName":"Trivalent OPV Sanofi Pasteur","genericName":"Trivalent OPV Sanofi Pasteur","companyName":"Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.","companyId":"laboratorios-de-biologicos-y-reactivos-de-m-xico-s-a-de-c-v","modality":"Biologic","firstApprovalDate":"","aiSummary":"Trivalent OPV Sanofi Pasteur is a vaccine that stimulates the body's immune response to protect against poliovirus. Used for Prevention of poliomyelitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}